Cutaneous Lupus Treatment Bangkok: English-Speaking Dermatologist for DLE / SCLE

Cutaneous Lupus Erythematosus (CLE) is a heterogeneous group of autoimmune skin diseases that may occur alone or as part of Systemic Lupus Erythematosus (SLE). At Siam Dermatology in Bangkok, our English-speaking, board-certified dermatologists provide international-standard CLE care including ANA workup, photoprotection counseling, hydroxychloroquine monitoring, and DLE scarring prevention.

CLE Subtypes

Acute CLE (ACLE): malar butterfly rash, photosensitive — strong association with SLE (>90%). Subacute CLE (SCLE): annular polycyclic or papulosquamous, sun-exposed shoulders/arms, anti-Ro/SSA+ — 50% meet SLE criteria. Drug-induced SCLE: hydrochlorothiazide, terbinafine, TNF-inhibitors. Chronic CLE: Discoid LE (DLE) — indurated scaly plaques with central atrophy, follicular plugging, dyspigmentation, scarring alopecia on scalp. Lupus profundus (panniculitis), lupus tumidus, chilblain LE are other variants.

SLE Workup

Every CLE patient is screened for SLE: ANA (titer + pattern), anti-dsDNA, anti-Sm, anti-Ro/La, complement (C3, C4), CBC, urinalysis with microscopy, renal function. EULAR/ACR 2019 criteria are used to confirm SLE diagnosis. Risk of progression CLE→SLE: DLE 5-10%, SCLE 10-15%, ACLE >90%. Yearly review for systemic involvement is essential.

Treatment Pathway

Photoprotection: broad-spectrum SPF 50+ daily, sun-protective UPF 50+ clothing, hats, avoidance of midday UV. UV exposure can trigger SLE flares. Topical: high-potency corticosteroids and tacrolimus 0.1% for non-scarring lesions. Intralesional triamcinolone 5-10 mg/mL for thick DLE plaques. Systemic first-line: hydroxychloroquine 5 mg/kg/day (max 400 mg) — baseline ophthalmology then annual screening for retinal toxicity after 5 years per AAO 2022 guidelines. Refractory: add quinacrine, switch to chloroquine, then methotrexate, mycophenolate mofetil, dapsone, thalidomide, or belimumab/anifrolumab for severe SLE. DLE scarring requires aggressive early treatment to prevent permanent alopecia.

Frequently Asked Questions

Will my lupus skin disease progress to systemic lupus? It depends on the subtype. Discoid lupus progresses to systemic lupus in 5-10%, subacute in 10-15%, and acute cutaneous lupus is almost always part of systemic disease. Annual screening for kidney, joint, and hematologic involvement is essential regardless of subtype.

Is hydroxychloroquine safe long-term? Yes, when properly monitored. Risk of retinal toxicity is <1% in first 5 years at 5 mg/kg/day or less, increasing thereafter. We arrange baseline ophthalmologic exam and yearly screening after year 5, per AAO guidelines. Smokers respond less well, so smoking cessation is strongly advised.

Why is sunscreen so important? Ultraviolet light is the strongest known trigger for cutaneous lupus flares and SLE activity. We recommend broad-spectrum SPF 50+ daily applied generously, reapplied every 2 hours when outdoors, plus UPF clothing and avoidance of peak UV. This is non-negotiable for disease control.

Can DLE hair loss grow back? Only if treated before scarring develops. Once scarring is established the follicles are permanently lost. Early DLE with active inflammation but intact follicles can regrow with intralesional steroids + hydroxychloroquine. This is why prompt evaluation and treatment is critical.

📞 Book at Siam Dermatology — LINE @dr.patskinclinic | Call +66 61 448 7000